Citations

Clear

1792 citation(s) found for "Stephanie".

Decompression with or without Duraplasty for Chiari I and Syringomyelia
Limbrick, David D. , Shannon, Chevis N., Bayman, Emine O., Meehan, Thanda, Kallem, Marisa, Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory, Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa C., Bauer, David, Bethel-Anderson, Tammy, Bierbrauer, Karin, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel, Daniels, David J., Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G., Eskandari, Ramin, Gannon, Stephen R., Grant, Gerald A., Greene, Stephanie, Gross, Naina L. , Guillaume, Daniel J. (Daniel James), Hankinson, T., Heuer, Gregory, Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M., Keating, Robert F., Kelly, Michael P., Kennedy, Elaine, Krieger, Mark D., Kulkarni, Abhaya V., Labuda, Rick, Leonard, Jeffrey R., Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon, McEvoy, Sean D., Niazi, Toba N., Oakes, Jerry, Olavarria, Greg, O’Neill, Brent R., Poppe, Dorothy, Ragheb, John, Reynolds, Lisa, Selden, Nathan R., Shah, Manish N., Smyth, Matthew D., Spears, Sandy, Stone, Scellig , Strahle, Jennifer M., Tamber, M, Tramelli, Gina, Tuite, Gerald F. , Vance, Haley, Wait, Scott D. , Wellons, John C. , Whitehead, WE, Yahanda, Alexander T., Yan, Yan, Dacey, Ralph G. , Park, Tae Sung, Torner, James C., Kelly, Michael P. , Torner, James C. , Dlouhy, Brian J , Iskandar, Bermans J , Yahanda, Alexander T , Kelly, Michael P , Limbrick, David D. , Bayman, Emine O. , Ahmed, Raheel , Albert, Gregory W. , Bierbrauer, Karin S. , Daniels, David J. , Ellenbogen, Richard G., Graupman, Patrick C. , Greenberg, Jacob K , Greenfield, Jeffrey P. , Guillaume, Daniel, Iantosca, Mark, Jackson, Eric M., Jallo, George I. , Johnston, James M. , Keating, Robert F., Kennedy, Elaine, Kulkarni, Abhaya V. , McComb, J. Gordon , McKinstry, Robert C. , Menezes, Arnold H. , Poppe, Dorothy , Ragheb, John , Reeves, Samuel, Reynolds, Lisa, Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Strahle, Jennifer M. , Tamber, Mandeep S. , Tyler‐Kabara, Elizabeth C. , Vance, E. Haley, Yahanda, Alexander T. , Park, Tae Sung

Mayo Clinic

New England Journal of Medicine | May 27, 2026 | Volume: 394 | Issue: 20 | Pages: 2015-2025

10.1056/nejmoa2402821 | PMID 42202320 Get It

Utilization and outcomes of minimally invasive resection in patients with neuroblastoma and Wilms tumor in a national cohort.
Day, Courtney N. , Habermann, Elizabeth B., Habermann, Elizabeth B. , Polites, Stephanie F.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 10043-10043

10.1200/jco.2026.44.16_suppl.10043 Get It

10043 Background: Tumor resection is a cornerstone of therapy for neuroblastoma (NB) and Wilms tumor (WT). Minimally invasive surgical approaches such as laparoscopic or robotic tumor resection hold promise to reduce surgical morbidity while maintaining excellent oncologic outcomes. This study aims to determine the utilization and outcomes of laparoscopic and robotic resection of NB and WT among children in a national cohort, hypothesizing that utilization is increasing over time and outcomes are not inferior to open resection. Methods: A retrospective cohort analysis of patients <18 years old in the 2020-2023 National Cancer Database who underwent resection of NB or WT was performed. Surgical approach trends were assessed via Cochran-Armitage tests. Conversions to open surgery, length of stay (LOS), and readmissions were compared between approaches using Kruskal-Wallis, Chi-square, and Fisher’s exact tests. Results: Among 1,262 children who underwent resection of NB (n=581) or WT (n=681), open procedures were most common (83.4%), followed by laparoscopic (13.9%), and robotic (2.7%). Utilization of each approach was stable over time aside from increased robotic resection of NB from 0% to 4% (p=.024). Approach did not vary by patient age (Table 1). Median WT size and lymph node yield were similar between approaches (both p>.05). In NB, laparoscopic procedures were performed on smaller tumors than open or robotic (p<.001). There were no robotic conversions to open; 11.4% of laparoscopic procedures were converted without change over time or difference between NB and WT (both p>.05). Median LOS was greater for open procedures than laparoscopic or robotic (p<.001). Readmission rates (p=.64) and margin status (p=.63) were similar between approaches. Outcomes did not vary by diagnosis. Conclusions: Utilization of minimally invasive approaches for NB or WT resection remains low despite noninferior or improved outcomes. Efforts to safely increase utilization are needed, especially for robotics, so that survivorship can be improved through reduced surgical morbidity. Differences in patient characteristics and outcomes by surgical approach. Characteristic or Outcome Open Laparoscopic Robotic p value Age in years (median, IQR) 3 (1, 4) 3 (1, 5) 3 (1, 7) 0.08 % female 53% 53% 44% 0.59 NB tumor size in mm (median, IQR) 72 (50, 101) 47 (35, 71) 70 (51, 86) <0.001 WT tumor size in mm (median, IQR) 110 (75, 140) 115 (93, 150) 93 (54, 125) 0.10 % metastatic disease 33% 30% 15% 0.07 % neoadjuvant therapy 35% 27% 22% 0.014 % conversion to open n/a 11% 0% 0.05 Negative margins 86% 83% 96% 0.63 # Lymph nodes assessed in WT (median, IQR) 5 (3, 8) 6 (3, 10) 4 (3, 9) 0.62 LOS in days (median, IQR) 5 (4, 7) 4 (2, 6) 4 (1, 5) <0.001 % readmission 15% 14% 9% 0.64
Frailty and postoperative outcomes following craniopharyngioma resection: a multicenter Registry for Adenomas of the Pituitary and Related Disorders analysis
Chen, Anthony Yulin, Feng, Rui, Collopy, Calen, Rennert, Robert C., Couldwell, William T., Kshettry, Varun R., Gardner, Paul, Silverstein, Julie M., Kim, Albert H., Barkhoudarian, Garni, Kelly, Daniel, Pacione, Donato , Suryadevara, Carter M. , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Wu, Kyle C., Prevedello, Daniel M., BENJAMIN, CAROLINA, Catalino, Michael P., Mamelak, Adam, Cheok, Stephanie K., Zwagerman, Nathan T., Gompel, Jamie J. Van, Fernandez-Miranda, Juan C., Yuen, Kevin C. J., Little, Andrew S., Karsy, Michael, Evans, James J., Karsy, Michael , Barkhoudarian, Garni , Palit, Sandhya R. , Karsy, Michael , Kelleher, Sean T., Rennert, Robert C , Couldwell, William T. , Kshettry, Varun R. , Silverstein, Julie , Kim, Albert H , Kelly, Daniel, Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Prevedello, Daniel M. , Catalino, Michael Paul, Mamelak, Adam N. , Cheok, Stephanie , Zwagerman, Nathan T. , Gompel, Jamie J. Van , Fernandez‐Miranda, Juan C. , Yuen, Kevin C.J. , Little, Andrew S. , Evans, James J.

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E7

10.3171/2026.2.focus251160 | PMID 42224740 Get It

OBJECTIVE Frailty is a known predictor of adverse outcomes in pituitary surgery, yet its impact regarding craniopharyngioma remains unclear. The authors assessed preoperative frailty, measured by the 11-factor modified frailty index (mFI-11), and its association with perioperative morbidity among adult patients undergoing craniopharyngioma surgery. METHODS Using the Registry for Adenomas of the Pituitary and Related Disorders (RAPID) database, the authors performed a retrospective cohort study of the records of patients ≥ 18 years of age who underwent craniopharyngioma surgery between June 2007 and November 2024. Patients were stratified into the following categories according to their numeric mFI-11 score: fit (scores 0 and 1), managing well (scores 2 and 3), and mildly frail (scores 4–6). Primary outcomes included hospital length of stay (LOS) and discharge disposition. Secondary outcomes included 90-day readmission, surgical outcomes, and complications. Multivariable analyses were performed to identify independent predictors of hospital LOS and non-home discharge, adjusting for age, surgeon experience, American Society of Anesthesiologists class, complications, and surgical approach. RESULTS Among 278 patients (221 fit, 43 managing well, 14 mildly frail), higher-frailty patients were older (mean age 47.8 ± 16.1 years in fit vs 60.1 ± 12.5 years in managing well vs 67.6 ± 8 years in mildly frail, p < 0.001) and more likely to present urgently (24.2% vs 36.4% vs 78.6%, p = 0.001). Gross-total resection was achieved less frequently in frail patients (44.8% vs 24.3% vs 23.1%, p = 0.030). Overall complication rates were similar; however, increasing frailty was associated with higher rates of postoperative mortality (0% vs 2.8% [1/36] vs 7.7% [1/13], p = 0.018), pneumonia (0.5% [1/195] vs 2.8% [1/36] vs 15.4% [2/13], p = 0.006), and reintubation (2.6% [5/195] vs 2.8% [1/36] vs 30.8% [4/13], p = 0.002). Higher frailty was associated with a stepwise rise in median [IQR] LOS (5 [3–8] days vs 7 [4–12] days vs 13 [6.5–21.8] days, p < 0.001) and remained an independent predictor of extended LOS on multivariable analysis (β = 1.729 per point, p = 0.006). Rates of non-home discharge showed a similar pattern (9.2% vs 30.0% vs 64.3%, p < 0.001), with frailty independently predicting non-home discharge (OR 2.352, 95% CI 1.527–3.822). Unplanned 90-day readmission rates were significantly higher in the mildly frail cohorts (22.5% vs 45.7% vs 53.8%, p = 0.002). CONCLUSIONS The mFI-11 scores independently predicted perioperative morbidity following craniopharyngioma resection. Incorporating frailty screening into preoperative screening may improve risk stratification, family and patient counseling, and discharge planning.
Predictors of hospital length of stay, discharge disposition, and readmission after craniopharyngioma surgery: a multicenter study from the RAPID database
Tenhoeve, Samuel A. , Tang, Anthony , Orton, Cody , Gautam, Diwas, Abdul-Rahman, Nana-Hawwa, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Benjamin, Carolina G., Gompel, Jamie J. Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Zenonos, Georgios A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Gardner, Paul A., Rennert, Robert C., Karsy, Michael , Mukherjee, Debraj , Barkhoudarian, Garni , Van Gompel, Jamie, Palit, Sandhya R. , Mukherjee, Debraj , Karsy, Michael , Gautam, Diwas , Abdul‐Rahman, Nana‐Hawwa , Silverstein, Julie , Kim, Albert H , Evans, James J., Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Morshed, Ramin A. , Blackburn, Spiros L., Beer‐Furlan, André , Couldwell, William T. , Gardner, Paul A. , Rennert, Robert C

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E6

10.3171/2026.2.focus251047 | PMID 42224727 Get It

OBJECTIVE Craniopharyngiomas are benign intracranial tumors that can be difficult to manage operatively and often result in postoperative complications and prolonged recovery. Understanding the factors that influence length of stay (LOS), discharge disposition, and readmission can guide perioperative planning and patient counseling. The authors examined the clinical, radiographic, and surgical predictors of extended LOS (eLOS), nonhome discharge, 90-day readmission, and hospitalization ratio (HR) after craniopharyngioma resection using a large, multicenter cohort. METHODS A retrospective analysis was conducted using the Registry of Adenomas of the Pituitary and Related Disorders database, encompassing 469 patients who underwent craniopharyngioma resection at 14 US academic centers from 2011 to 2025. Patients were stratified by 4 outcomes: eLOS (> 75th percentile), discharge to home versus skilled nursing facility/rehabilitation, 90-day hospital readmission, and hospitalization ratio (i.e., integration of initial and readmission LOS). Multivariable logistic regression models identified independent predictors for each outcome among patient and surgical variables. RESULTS An eLOS (> 10 days) was independently associated with preoperative memory loss (OR 3.75, 95% CI 1.95–7.21), gait imbalance (OR 5.90, 95% CI 1.53–22.70), and postoperative complications (OR 4.07, 95% CI 2.34–7.06). The use of a nasoseptal flap was protective against an eLOS (OR 0.52, 95% CI 0.28–0.93). Discharge to home was predicted by an endoscopic approach (OR 3.87, 95% CI 1.78–8.44) and postoperative intact thirst (OR 2.22, 95% CI 1.05–4.66) and negatively predicted by preoperative diabetes mellitus (OR 0.21, 95% CI 0.09–0.50), LOS (OR 0.87, 95% CI 0.84–0.91), and postoperative cognitive dysfunction (OR 0.30, 95% CI 0.13–0.72). Among 385 patients with follow-up data, a 90-day readmission was independently associated with postoperative complications (OR 5.62, 95% CI 3.12–10.13), preexisting coronary artery disease (OR 4.30, 95% CI 1.46–12.69), and postoperative cognitive dysfunction (OR 3.33, 95% CI 1.76–6.44). A higher HR was associated with diabetes mellitus (unstandardized B 0.059, 95% CI 0.010–0.108, p = 0.02), postoperative complications (unstandardized B 0.054, 95% CI 0.021–0.086, p = 0.001), and postoperative cognitive dysfunction (unstandardized B 0.049, 95% CI 0.006–0.092, p = 0.02). Tumor pathologic subtype and size, prior treatment, extent of resection, and surgeon experience were not directly predictive of outcomes. CONCLUSIONS Cognitive and functional status, systemic comorbidities, and postoperative complications, in addition to surgical approach, are important predictors of the early clinical course after craniopharyngioma surgery. Early identification of high-risk patients may help to guide treatment decisions, improve discharge planning, and reduce healthcare utilization.
Response to Letter to the Editor: “Esophageal Screening During Videofluoroscopic Swallow Study: Roadblocks and Roadmaps”
Watts, Stephanie , Gregor, Jessica W. , Gregor, Jessica W

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | May 22, 2026 | Volume: 11 | Issue: 4 | Pages: 1405-1407

10.1044/2026_persp-26-00035 Get It

Reply: Evaluation of the accuracy and readability of large language model responses on menopause and hormone therapy
Karam, J H, Shufelt, Chrisandra, Safwan, Nancy , Kapoor, Ekta, Christmas, Monica M., Faubion, Stephanie S., Shufelt, Chrisandra , Shufelt, Chrisandra L , Karam, Jana, Kapoor, Ekta , Christmas, Monica , Faubion, Stephanie S.

Mayo Clinic

Menopause | May 22, 2026 | Volume: 33 | Issue: 6 | Pages: 757-758

10.1097/gme.0000000000002792 | PMID 42170884 Get It

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study
Muffly, Lori , Frey, Noelle V. , Roloff, Gregory W. , Park, Jae H, Advani, Anjali S. , Bachanová, Veronika , Cassaday, Ryan D. , Daunov, Michael , Dykes, Kaitlyn C. , Gatell, Vivian Irizarry , Jamy, Omer , Kota, Vamsi, Kumaran, Muthu, O’Dwyer, Kristen M. , Oliai, Caspian , Schwartz, Marc S., Solh, Melhem M., Stock, Wendy, Tsai, Stephanie B., Ulrickson, Matthew L., Vasu, Sumithira, Leonard, Jessica T., Aldoss, Ibrahim, Dholaria, Bhagirathbhai R , Advani, Anjali S , Cassaday, Ryan D , Daunov, Michael , Dykes, Kaitlyn C , Grunwald, Michael , Hilal, Talal , Hill, LaQuisa C , Jamy, Omer , Lin, Chenyu , Logan, Aaron C , Luskin, Marlise R , O'Dwyer, Kristin , Oliai, Caspian H , Oluwole, Olalekan O , Sasine, Joshua , Wang, Eunice S. , Strickland, Stephen Anthony , Leonard, Jessica T , Shah, Bijal , Bachanova, Veronika , Muffly, Lori , Frey, Noelle V , Roloff, Gregory W , Dholaria, Bhagirathbhai , Grunwald, Michael R. , Hilal, Talal , Hill, LaQuisa C. , Kota, Vamsi , Oluwole, Olalekan O. , Sasine, Joshua , Solh, Melhem , Stock, Wendy , Tsai, Dr. Stephanie B., Ulrickson, Matthew L. , Vasu, Sumithira , Yalniz, Fevzi , Shah, Bijal , Aldoss, Ibrahim

Mayo Clinic

Blood | May 19, 2026 | Volume: 148 | Issue: 6 | Pages: 657-668

10.1182/blood.2026033559 | PMID 42154904 Get It

Abstract The use of chimeric antigen receptor (CAR) T-cell therapy is increasing for adult B-cell acute lymphoblastic leukemia (B-ALL), with 3 CD19 CAR T-cell products commercially available. Several key clinical questions related to best practices for CAR T-cell administration in this population exist, and limited prospective randomized trials have been conducted to fill these knowledge gaps. Thus, to help guide clinical practice, we conducted a modified Delphi study to develop and validate consensus recommendations on the administration of commercially available CAR T-cell therapy for adults with B-ALL. Consensus panelists (n = 9) included principal investigators (PIs) from Real World Outcomes Collaborative of CAR T-Cell Therapy in Adult ALL (ROCCA) consortium sites and were selected based on expertise and CAR T-cell center volume. Final panel consensus recommendations were distributed for rating by the remaining PIs from ROCCA consortium sites, which served as the validation group (n = 27). Consensus topics included patient selection, bridging and pre–CAR T-cell leukemia staging, lymphodepletion, and CAR T-cell treatment setting, specific toxicity prevention and management, post–CAR T-cell response assessment and disease monitoring, and the role of consolidation and/or maintenance therapies after CAR T-cell therapy. Initially, 58 recommendation statements were evaluated for consensus. After 2 panel meetings, a total of 34 statements achieved consensus rating among the expert panel. After rating by the validation group, all but 1 recommendation statement continued to meet consensus, for a total of 33 consensus recommendation statements on the administration of CAR T-cell therapy in adult B-ALL.
A29-05 Objective Sleep Measures May Improve Machine Learning Prediction of Home-based Pulmonary Rehabilitation Engagement Among Patients With Chronic Obstructive Pulmonary Disease
Zawada, S, Faust, L, Enayati, M, Benzo, R, Fortune, E, Zawada, Stephanie , Faust, Louis , Enayati, Moein , Benzo, R, Fortune, Emma

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6093 Get It

Abstract Rationale Despite its effectiveness at improving outcomes in patients with COPD, pulmonary rehabilitation (PR) attrition rates are high, often exceeding 50%. Fully remote programs, like home-based PR (HBPR), face additional challenges engaging patients in real-world settings. With the growing adoption of wearables, sensor-derived behavioral measures, like sleep patterns, may identify patients most likely to benefit from remote PR. This study evaluated whether incorporating baseline sleep measures from a wrist-worn activity monitor in machine learning (ML) models improved the prediction of 12-week engagement with HBPR in patients with COPD. Methods Among participants (n = 124), the following sleep measures were collected for 1 week before HBPR: sleep duration (min), standard deviation of sleep duration, wake-after-sleep-onset (WASO) (min), standard deviation of WASO, number of awakenings, length of awakenings (min), activity counts, movement index, movement fragmentation index, and sleep fragmentation index. Sleep measures were processed (1) using a previously validated Tudor-Locke algorithm and (2) applying partial least squares-discriminant analysis (PLS-DA) to generate a single latent variable (Composite Sleep Health Score) for inclusion in models. Engagement was defined as completion of one or more recommended activities per week for the full program duration (12 weeks). To determine if the inclusion of objective sleep measures improved the prediction of HBPR engagement, nested model comparisons for parametric (logistic regression and SVM) and non-parametric (decision tree and naïve bayes) ML models were performed. A sensitivity analysis (SA) replaced the Composite Sleep Health Score with sleep regularity (duration and WASO) measures only. Results In models adjusted for age, sex, Charlson Comorbidity Index, current smoker status, modified Medical Research Council (mMRC), and forced expiratory volume in 1 second (FEV1), the inclusion of the Composite Sleep Health Score significantly improved the prediction of 12-week engagement only in SVM models (AUC 0.755; p = 0.007). Specificity (18.2%) and accuracy (68.5%) also improved by 27.3% and 7.3%, respectively. The Composite Sleep Health Score and mMRC scores ranked most frequently as the variables of highest importance. Identical trends were observed in the SA. Conclusion Although preliminary, these findings support additional investigation into the use of wearable-derived sleep measures to improve screening for HBPR eligibility, identifying patients who will clinically benefit from fully remote PR. Building on these primary findings, future researchers should carefully select variables for model inclusion and initiate new hypotheses elucidating the link between objective sleep measures and HBPR outcomes in COPD patients. This abstract is funded by: NIH R56 HL173214, NIH R01 HL140486, and the Robert D. and Patricia E. Kern Center for the Science of Health Delivery
Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Lapierre, Stephanie , You, Zhiying , Gitomer, Berenice Y. , Chapman, Arlene B. , Harris, Peter, Perrone, Ronald D. , Rahbari-Oskoui, Frederic F. , Chonchol, Michel, Nowak, Kristen L. , Harris, Peter C. , Lapierre-Nguyen, Stephanie , Gitomer, Berenice Y , Abebe, Kaleab Z , Chapman, Arlene B. , Harris, Peter C , Torres, Vicente E , Rahbari-Oskoui, Frederic F , Torres, Vicente E , Nowak, Kristen L , You, Zhiying , Chonchol, Michel

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1681/asn.0000001131 | PMID 42149684 Get It

Key Points In an observational cohort of mostly non-Hispanic White women, pregnancy was not associated with later-life accelerated kidney function decline. Pregnancy occurring during the HALT Progression of Polycystic Kidney Disease (HALT-PKD) trial was not associated with kidney disease progression relative to women who did not become pregnant. Prior evidence indicates that adverse pregnancy outcomes may be involved in autosomal dominant polycystic kidney disease progression; pregnant women should be closely monitored. Background Data are conflicting regarding whether pregnancy influences disease progression in women with autosomal dominant polycystic kidney disease (ADPKD). This study examined whether pregnancy or number of pregnancies was associated with kidney disease progression in women with ADPKD. Methods Women with early- (study A) and late-stage (study B) ADPKD from the HALT Progression of Polycystic Kidney Disease (HALT-PKD) trial were included to examine the association between self-reported number of pregnancies (categorical predictor: no pregnancy versus 1–2 pregnancies and ≥3 pregnancies), annual slope of eGFR, annual percent change in total kidney volume (%ΔTKV), and a composite outcome (kidney failure, 50% decline in eGFR, or death) using multivariable linear regression and Cox proportional hazard models. In addition, women who became pregnant, had full-term pregnancies, and available data during study participation ( n =13) were propensity matched (1:4) to women who were not pregnant during study participation, and a mixed model was applied to determine the association of pregnancy with eGFR slope and %ΔTKV. Results Across all analyses, 455 women with a median age of 45 (interquartile range, 38–50) years and eGFR of 69±25 ml/min per 1.73 m 2 at baseline were included. One hundred ninety-nine women had 1–2 pregnancies, and 165 women had ≥3 pregnancies. There was no association of 1–2 pregnancies or ≥3 pregnancies (versus no pregnancies) with eGFR slope ( β -estimate [95% confidence interval (CI)]; 1–2 pregnancies: 0.22 [−0.44 to 0.89]; ≥3 pregnancies: −0.46 [−1.16 to 0.25]), %ΔTKV ( β -estimate [95% CI]; 1–2 pregnancies: 0.92 [−0.34 to 2.17]; ≥3 pregnancies: 0.69 [−0.67 to 2.04]), or time to composite outcome (hazard ratio [95% CI]; 1–2 pregnancies: 1.04 [0.56 to 1.93]; ≥3 pregnancies: 1.48 [0.78 to 2.77]) in adjusted models. Moreover, there was no difference in annual eGFR slope ( β -estimate: −0.14 [95% CI, −2.72 to 2.44]) and %ΔTKV ( β -estimate: 0.04 [95% CI, −3.74 to 3.82]) in women who became pregnant matched to women who did not became pregnant during their participation in the study. Conclusions Pregnancy was not associated with ADPKD progression among women with early- and late-stage ADPKD enrolled in the HALT-PKD trial.
Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas
Yefet, Leeor S, Landry, Alexander , Rogers, C Leland, WANG, J, Patil, Vikas, Gui, Chloe, Ajisebutu, Andrew, Ellenbogen, Yosef , Wei, Qingxia , Singh, Olivia, Szot, Christopher, Barani, Igor J. , Straza, Michael , Shu, Hui-Kuo G, Hunter, Grant, Panet-Raymond, Valérie , Shi, Wenyin, Kavanagh, Brian D. , Gunter, Tyler, Robinson, Clifford, Pugh, Stephanie L. , Mehta, Minesh P, Chakravarti, Arnab, Nassiri, Farshad, Aldape, Kenneth, Zadeh, G Z, Gui, Chloe , Wang, Justin Z , Liu, Jeff , Gui, Chloe , Ellenbogen, Yosef , Singh, Olivia , Jordan, Richard C , Barani, Igor J , Straza, Michael W , Shu, Hui-Kuo G , Pointer, Kelli B , Hunter, Grant , Panet-Raymond, Valerie , Shi, Wenyin , Perlow, Haley K , Kavanagh, Brian D , Gunter, Tyler , Robinson, Clifford , Dicker, Adam P , Mehta, Minesh P , Chakravarti, Arnab , Aldape, Kenneth , Zadeh, Gelareh , Yefet, Leeor S. , Rogers, C. Leland, Wang, Justin Z. , Patil, Vikas , Ajisebutu, Andrew, Mansouri, Sheila , Shi, Wenyin , Perlow, Haley K. , Gunter, Tyler C., Dicker, Adam P. , Mehta, Minesh P. , Chakravarti, Arnab , Nassiri, Farshad

Mayo Clinic

Neuro-Oncology | May 14, 2026 | Volume: 28 | Issue: 7 | Pages: 1727-1740

10.1093/neuonc/noag081 | PMID 42143623 Get It

Abstract Background Meningiomas exhibit clinical heterogeneity. Radiotherapy (RT) remains the only adjuvant therapy, but tumor-control is variable, and biomarkers are limited. NRG/RTOG-0539 is the first prospective phase 2 trial to stratify meningioma patients for adjuvant RT based on clinical risk. Here, we apply modern molecular tools to this cohort and identify correlates of RT response. Methods Tumor tissue from 100 RTOG-0539 patients was profiled using DNA methylation arrays, RNA sequencing, and whole-exome sequencing. Recurrence scores, Molecular Groups, gene expression, and copy number alterations were compared across clinical groups and between RT responders and non-responders; non-response was defined as progression or death within 3 years. Results Modern grading criteria, including brain invasion, TERT mutation, CDKN2A/B deletion, and 1p/1q status, would reclassify 10% of tumors and alter treatment group assignment in 7%. Non-responders to RT exhibited more frequent 1p and 14q loss, and more copy number alterations. Transcriptomic and epigenetic profiling revealed immune-related signatures in responders and cell cycle–related pathways in non-responders, several of which overlapped with targets of vorinostat, a histone deacetylase inhibitor previously validated in aggressive meningioma models. The Proliferative Molecular Group was an independent predictor of post-RT recurrence in multivariable analysis, outperforming WHO grade. Conclusion Multi-omic analysis of the NRG/RTOG-0539 cohort shows that updated WHO grading criteria, incorporating molecular and cytogenetic features, improve risk stratification. However, molecular classification, particularly the Proliferative group, remains an independent and stronger predictor of RT response. These findings support integrating molecular biomarkers alongside modern grading frameworks to guide treatment and trial design in meningioma. Clinical Trial Information NCT00895622.